Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer

Fig. 3

Pathological complete response rates according to molecular subtype. a Pathological complete response rates according to pertuzumab treatment for the BluePrint standard subtypes. Patients with Basal- and Luminal-type tumors are grouped together for the non-HER2-type category. b Pathological complete response rates according to pertuzumab treatment for the BluePrint dual subtypes. Only subtypes with n > 10 are shown. *** Fisher exact test p-value < 0.001. NS not significant

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us